Australia's Imugene hits one week high after cancer treatment trial clears milestone

Imugene

02/02/2023 02:54

** Shares of cancer-focused biopharma Imugene  IMU.AX  rise
as much as 8.9% to A$0.153, hits highest level since Jan 25
    ** Stock sees best day since Jan 5 if gains hold 
    ** Co says its phase one study to evaluate safety of Vaxinia
cleared cohort 2 of both arms of the monotherapy trial
    ** Vaxinia will be used to treat patients with metastatic or
advanced solid tumours
    ** Clearance now allows co to open a cohort 1 of a
combination study with usage of Pembrolizumab, among others
    ** Pembrolizumab is a drug used to treat melanoma, lung
cancer, etc 
    ** About 16 mln shares change hands, in-line with IMU's
30-day average volume
    ** YTD, IMU down 3.5% this year 
 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))